Medicare Value-Based Model May Provide Test For Biosimilars – At Some Point
Rheumatoid arthritis will be included in broaden clinical categories for year two of the value-based insurance design pilot; it may be an interesting test case for biosimilars.
You may also be interested in...
Part D has reached a significant milestone: for the first time, a majority of beneficiaries in the outpatient drug program are also enrolled in fully integrated Medicare Advantage plans. That opens up opportunities to learn more about value-based designs and longer-term outcomes.
Participating plans to share in savings if they stay below spending target for Part D catastrophic phase and repay 10% of any excess spending; CMS also updates its VBID model.
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.